Chase W Miller, Casey A Scroggins, Shannon L Wuller, Marcella J Hegarty, John A Utrup, Camari D Griffin, John S Zaky, Michelle L James, Harrison D Sciulli, David G Miller, Joseph M Coney
{"title":"Real-World Anatomical Outcomes of Suprachoroidal Triamcinolone Acetonide Injections in a Large Retinal Practice over a 4-Year Period.","authors":"Chase W Miller, Casey A Scroggins, Shannon L Wuller, Marcella J Hegarty, John A Utrup, Camari D Griffin, John S Zaky, Michelle L James, Harrison D Sciulli, David G Miller, Joseph M Coney","doi":"10.1177/10807683261461177","DOIUrl":"10.1177/10807683261461177","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the clinical role, durability, anatomical response, and safety for suprachoroidal triamcinolone acetonide (SCTA) (Xipere) in routine clinical practice.</p><p><strong>Methods: </strong>Data were manually extracted from health records at a high-volume retina practice in Cleveland, Ohio. All patients with noninfectious inflammatory macular edema undergoing SCTA (≥1 billing code) between October 25, 2021, and July 17, 2025, were included. Patients with known systemic autoimmune or infectious associations were excluded. Unique eyes were defined by MRN + laterality, with \"OU\" entries split into OD/OS. Patient demographics, underlying diagnosis categorization, time between first and second injection (for eyes with ≥2 injections) were summarized. Pre- versus post-treatment central retinal thickness (CRT) and intraocular pressure (IOP) were compared via paired t-tests.</p><p><strong>Results: </strong>A total of 177 patients (195 eyes) received 340 SCTA injections for macular edema associated with an underlying diagnosis of intermediate uveitis (10%), pseudophakic cystoid macular edema (31%), and posterior uveitis (59%). The time between first and second injection was approximately 5 months [SD ± 72.5; median 144 (min 35, max 427)]. From baseline to follow-up, mean CRT decreased by 103 µm [95% CI: (-122,-83.2), <i>P</i> < 0.001], while IOP increased minimally [mean difference 0.7 mmHg, 95% CI: (-0.02, 1.43), <i>P</i> = 0.057]; and was medically managed when elevated.</p><p><strong>Conclusions: </strong>In this real-world cohort, findings suggest that SCTA achieves robust anatomical improvement, a favorable IOP profile, and prolonged durability across patients with inflammation-related macular edema.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"653-657"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148240969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ocular Toxicity of Systemic 5-Fluorouracil Chemotherapy: Role of Lacrimal Gland Transporters.","authors":"Manthan S Hiremath, Mounika Varkala, Manisha Malani, Swati Singh, Jayabalan Nirmal","doi":"10.1177/10807683261467574","DOIUrl":"10.1177/10807683261467574","url":null,"abstract":"<p><strong>Purpose: </strong>5-Fluorouracil (5-FU) is a commonly used antimetabolite in cancer therapy. Patients (25% to 38%) undergoing chronic systemic 5-FU chemotherapy are affected by ocular toxicity and require cessation of therapy to manage ocular complications. However, the mechanism by which 5-FU crosses the blood-tear barrier is not well understood. The current study investigates the role of organic anion transporters (OAT2 and 3) in the blood-tear barrier of the lacrimal gland, in trafficking 5-FU into the ocular surface.</p><p><strong>Method: </strong>Computer simulations were performed to determine the substrate specificity of 5-FU for OAT isoforms. Tear pharmacokinetic studies of intravenous 5-FU were conducted in rabbits (<i>n = 3</i> per group), with and without OAT blockade. The ocular adverse effect of 5-FU was assessed <i>in vitro</i> using human corneal epithelial cells (HCEC). Furthermore, the potential of artificial tears to reduce ocular accumulation of 5-FU was evaluated.</p><p><strong>Results: </strong>Computational studies indicated that 5-FU is a substrate for OAT2. 5-FU was detected in the tear from systemic circulation (C<sub>max</sub> = 16.7 µg/mL) within five minutes of administration. The concentration of 5-FU reaching the ocular surface reduced HCEC viability in a concentration-dependent manner. Furthermore, topical pretreatment with OAT2 blockers reduced 5-FU exposure in tears by 1.53 to 2.96-fold, and prophylactic artificial tears containing polyethylene glycol 400 and propylene glycol achieved a 1.68-fold reduction in 5-FU exposure in tears.</p><p><strong>Conclusion: </strong>Blocking OAT-2 with eye drops (OAT2 blockers and artificial tears) reduced the tear concentration of 5-FU, suggesting a potential to minimize ocular toxicity of 5-FU in patients undergoing chemotherapy.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"687-695"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148439877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Liu Zheng, Jiaojiao Jiang, Jinqing Li, Xingyu Su, Shixiong Peng, Zhixiang Ding
{"title":"Integrated Bioinformatics and Explainable Machine Learning Analyses Reveal Mesenchymal Stem Cell Exosome-Related Biomarkers for Diabetic Retinopathy.","authors":"Liu Zheng, Jiaojiao Jiang, Jinqing Li, Xingyu Su, Shixiong Peng, Zhixiang Ding","doi":"10.1177/10807683261460674","DOIUrl":"10.1177/10807683261460674","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to identify potential biomarkers for diabetic retinopathy (DR) by focusing on genes associated with mesenchymal stem cell-derived exosomes (MSCs-Exo).</p><p><strong>Methods: </strong>By integrating DR transcriptome data with the protein dataset of MSCs-Exo, we utilized a comprehensive array of bioinformatics techniques, including weighted gene coexpression network analysis, Mfuzz clustering, and machine learning algorithms such as least absolute shrinkage and selection operator regression and random forest to pinpoint key genes. Functional mechanisms were explored through functional enrichment analysis, immune infiltration, and single-cell RNA sequencing. The immunohistochemistry and Western blotting were used for validation on DR mice models.</p><p><strong>Results: </strong>Our comprehensive analysis identified 16 hub genes associated with MSCs-Exo. Through the application of interpretable machine learning techniques, YBX1 and PSMA7 were further identified as central genes within this network. A predictive diagnostic model for DR was developed and validated using receiver operating characteristic curve analysis, which demonstrated modest diagnostic efficacy, as indicated by an area under the curve exceeding 0.7. Importantly, experimental validation showed that the protein expression levels of YBX1 and PSMA7 were significantly reduced in the retinal tissues of DR mice compared with the control group (<i>P</i> < 0.05). Functional enrichment analysis suggested that YBX1 and PSMA7 are involved in critical biological processes, specifically the regulation of protein and amino acid metabolism. In addition, immune infiltration results show that they are significantly associated with the immune dysregulation of DR, especially in CD4T memory cells. Single-cell analysis also supported the above finding.</p><p><strong>Conclusion: </strong>These findings suggest that YBX1 and PSMA7, derived from MSCs-Exo, may serve as potential biomarkers for DR. Further studies are needed to confirm their clinical utility and therapeutic relevance.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"707-721"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148274547","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ashley Nguyen, Michel M Sun, Jeff Penzner, Leon Nhan, Pin Li, Michael R Robinson
{"title":"Exploring the Role of the Zeis Gland in Dry Eye Disease Associated with Demodex Blepharitis.","authors":"Ashley Nguyen, Michel M Sun, Jeff Penzner, Leon Nhan, Pin Li, Michael R Robinson","doi":"10.1177/10807683261466536","DOIUrl":"10.1177/10807683261466536","url":null,"abstract":"<p><strong>Purpose: </strong>Demodex blepharitis is caused by <i>Demodex</i> mite infestation of the eyelash follicles and associated sebaceous glands (the glands of Zeis) and is often associated with tear film instability and dry eye disease (DED). Information on the role of Zeis glands is limited. This study used surrogate Zeis gland secretions in healthy volunteers to evaluate whether Zeis gland secretions could potentially contribute to the tear film lipid layer.</p><p><strong>Methods: </strong>The blinking status of each eye (partial or complete blinker) was assessed with interferometry. A surrogate Zeis gland secretion was applied with a moistened ophthalmic fluorescein strip across the center of the lower eyelid near the eyelash base. The presence of fluorescent dye in the tear film was evaluated at 2 and 5 min using a fluorescein angiography image acquisition system.</p><p><strong>Results: </strong>Forty eyes (20 subjects) were enrolled; 31 (77.5%) partial blinkers, 4 (10.0%) complete blinkers, and 5 (12.5%) nonblinkers that did not blink during the interferometry assessment. Fluorescent dye was detected in the tear film of 18 (45.0%) eyes at 2 min and 24 (60.0%) eyes at 5 min, with similar proportions of partial blinker, complete blinker, and nonblinker eyes demonstrating a fluorescent signal.</p><p><strong>Conclusion: </strong>A surrogate Zeis gland secretion accessed the tear film in most eyes, suggesting that Zeis gland secretions may contribute to the tear film. In Demodex blepharitis, abnormal or reduced lipid production from the Zeis and/or meibomian glands may contribute to DED. Further research is needed to clarify the underlying mechanisms of DED in patients with Demodex blepharitis.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"682-686"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148371714","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Necroptosis Driven by JAK/STAT-RIPK-MLKL Signaling Mediates Corneal Epithelial Erosion.","authors":"Hongyi Shen, Jiayi Jin, Jianqiang Zhang, Wanwen Shao, Jingyi Peng, Yan Yang, Yongxin Zheng, Liuxueying Zhong","doi":"10.1177/10807683261464756","DOIUrl":"10.1177/10807683261464756","url":null,"abstract":"<p><strong>Purpose: </strong>Recurrent corneal erosion (RCE) is an ocular surface disease with poor epithelial-stromal adhesion and limited therapies. This study aimed to elucidate the role of necroptosis, a pro-inflammatory form of programmed cell death, in the pathogenesis of corneal erosion.</p><p><strong>Methods: </strong>An <i>in vitro</i> UVB injury model was established in human corneal epithelial cells (HCEpiCs), followed by unbiased LC-MS/MS proteomics and pathway enrichment analysis. In parallel, a UVB-induced corneal erosion model was generated in C57BL/6 mice. To test therapeutic relevance, mice received a topical neutralizing anti-IFN-γ antibody or vehicle after injury. Corneal epithelial integrity and stromal architecture were assessed histologically, while activation of IFN-γ-JAK/STAT signaling, RIPK1/RIPK3/MLKL necroptosis, DAMP release, NLRP3 inflammasome assembly, and IL-1β maturation were examined using immunofluorescence, qRT-PCR, and Western blotting.</p><p><strong>Results: </strong>Proteomic profiling showed significant enrichment of necroptosis-related proteins following UVB exposure. UVB-treated corneal epithelium exhibited increased IFN-γ signaling and JAK/STAT activation, accompanied by elevated expression and activation of RIPK1, RIPK3, and MLKL. Necroptosis was associated with increased release of DAMPs, heightened NLRP3 inflammasome activation, and increased maturation/secretion of IL-1β. <i>In vivo</i>, topical anti-IFN-γ treatment reduced corneal epithelial defects, improved epithelial-stromal attachment, and decreased activation markers of the RIPK-MLKL and NLRP3-IL-1β pathways.</p><p><strong>Conclusions: </strong>Our findings unveil a novel and critical pathogenic axis in corneal erosion, where IFN-γ signaling drives a necroptotic-inflammatory loop. This work provides a new molecular framework for understanding corneal epithelial injury and identifies the IFN-γ-necroptosis axis as a promising therapeutic target for RCE.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"671-681"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148475708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Eyes on New Product Development-Number 136.","authors":"Gary D Novack","doi":"10.1177/10807683261491684","DOIUrl":"10.1177/10807683261491684","url":null,"abstract":"","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"613-614"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149027397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ian R Reekie, Laura Ramm, Eslam Al-Abadi, Sam P Gurney, Jerald William
{"title":"Systemic Infliximab Is Efficacious for the Control of Pediatric Uveitis Including in Adalimumab-Refractory Patients.","authors":"Ian R Reekie, Laura Ramm, Eslam Al-Abadi, Sam P Gurney, Jerald William","doi":"10.1177/10807683261454323","DOIUrl":"10.1177/10807683261454323","url":null,"abstract":"<p><p><i>Introduction:</i> This retrospective study aims to assess the efficacy of infliximab by intravenous infusion in treating pediatric non-infectious uveitis, including as a second-line anti-tumor necrosis factor (TNF) for patients with insufficient control from adalimumab.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"646-652"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Minna P Mustikka, Emily K-M Lindh, Karoliina Alm, Anna S Meller, Pernilla E S Syrjä, Simon A Pot, Marja R Raekallio, Juhana Honkavaara
{"title":"Vatinoxan Prevents Medetomidine-Associated Exophthalmos and Increased Glucose Concentrations in Blood and Aqueous Humor in Rats.","authors":"Minna P Mustikka, Emily K-M Lindh, Karoliina Alm, Anna S Meller, Pernilla E S Syrjä, Simon A Pot, Marja R Raekallio, Juhana Honkavaara","doi":"10.1177/10807683261463884","DOIUrl":"10.1177/10807683261463884","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate whether vatinoxan, a peripherally selective alpha<sub>2</sub>-adrenoceptor antagonist, prevents the acute, medetomidine-associated ophthalmic changes in rats.</p><p><strong>Methods: </strong>Adult male Wistar rats (<i>n</i> = 9 in each group) were randomly allocated to receive subcutaneous medetomidine 0.4 mg/kg and midazolam 2 mg/kg (MM), MM with vatinoxan 8 mg/kg (MM-V), or MM with regular insulin 1 IU/kg (MM-I). Macroscopic photography (to assess globe position) and slit-lamp biomicroscopy were performed, and blood glucose (BG) concentration, intraocular pressure (IOP), and central corneal thickness (CCT) were measured at intervals until 50 min post-treatment. Surgical anesthesia was then induced, and aqueous humor glucose (AHG) concentration was measured prior to euthanasia.</p><p><strong>Results: </strong>In MM and MM-I, exophthalmos worsened over time (<i>P</i> < 0.05) and compared to MM-V (<i>P</i> ≤ 0.04 for both). BG increased significantly over time (<i>P</i> < 0.001) only in MM, and AHG was significantly higher in MM than in MM-V and MM-I (<i>P</i> < 0.001). Lens clarity was decreased at 50 min in both MM (<i>P</i> = 0.002) and MM-I (<i>P</i> = 0.048), compared to MM-V. CCT was greater in MM-V than in MM at 50 min (<i>P</i> = 0.02). Corneal clarity remained unchanged. IOP declined in all groups but remained significantly higher in MM-V 10 min versus 50 min post-treatment (<i>P</i> = 0.02).</p><p><strong>Conclusions: </strong>Vatinoxan prevented pathological exophthalmos, lens opacification, the acute decline in IOP, hyperglycemia, and increased AHG in rats sedated with medetomidine-midazolam. Insulin similarly prevented hyperglycemia, but none of the ophthalmic changes. Acute alpha<sub>2</sub>-adrenoceptor agonist-mediated ophthalmic pathologies are independent from glycemic control.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"696-706"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148440335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Integrative Mechanistic Insights into Benzalkonium Chloride-Induced Cytotoxicity in Human Corneal Epithelial Cells.","authors":"Farzaneh Motafeghi, Ehsan Ghassemi Barghi, Jafar Gholami Gharab, Nasrin Ghassemi Barghi","doi":"10.1177/10807683261454329","DOIUrl":"10.1177/10807683261454329","url":null,"abstract":"<p><p>This study aimed to provide integrative mechanistic insights into benzalkonium chloride (BAK)-induced cytotoxicity in human corneal epithelial (HCE-T) cells, with a particular focus on the crosstalk between oxidative stress, DNA damage, ferroptosis-related events, apoptosis, and inflammatory signaling. HCE-T cells were exposed to increasing concentrations of BAK. Cell viability and membrane integrity were evaluated using MTT and lactate dehydrogenase assays, respectively. Oxidative stress was assessed by measuring intracellular reactive oxygen species (ROS) and antioxidant defense markers, including superoxide dismutase, catalase, glutathione peroxidase, and total antioxidant capacity. Genotoxic effects were analyzed using the comet assay, while lipid peroxidation was quantified by malondialdehyde levels. To distinguish cell death mechanisms, ferroptosis-related events (iron accumulation) and apoptotic markers (caspase-3/7 activity and DNA fragmentation via TUNEL assay) were examined. Additionally, inflammatory responses were evaluated by measuring the expression of interleukin-1β, interleukin-6, and tumor necrosis factor-α. The results demonstrate that BAK induces dose-dependent cytotoxicity in HCE-T cells, characterized by excessive ROS generation, impaired antioxidant defenses, significant DNA damage, and enhanced lipid peroxidation. Iron accumulation and oxidative lipid damage suggested a prominent role for ferroptosis-related events, occurring alongside apoptosis. Moreover, BAK exposure markedly activated inflammatory signaling pathways. Collectively, these findings highlight a complex, interconnected network of oxidative stress, DNA damage, ferroptosis-related events, and inflammation underlying BAK-induced corneal epithelial toxicity. This study provides mechanistic evidence relevant to ocular safety and preservative formulation strategies.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"633-645"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148038905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Beyond Acute Cytotoxicity: A Repair-Exhaustion Framework for Chronic Sublethal Benzalkonium Chloride Toxicity in Repeated Ophthalmic Exposure.","authors":"Xiang Zheng, Ahmed S Ibrahim, Sangly P Srinivas","doi":"10.1177/10807683261466785","DOIUrl":"10.1177/10807683261466785","url":null,"abstract":"<p><p>Benzalkonium chloride (BAK), a common preservative in multi-dose ophthalmic products, is often studied under acute high-dose exposure, which highlights overt damage to corneal epithelial cells. These studies tend to exaggerate the maximum cytotoxic effects and do not accurately reflect the gradual, cumulative damage seen during long-term use. By reviewing clinical, animal, and cellular data, we argue that repeated low-dose BAK exposure leads to barrier dysfunction, energy depletion, priming of inflammation, and impaired regeneration before significant cell death occurs. We suggest a repair-exhaustion model: minor injuries from repeated exposure are initially managed by membrane resealing and epithelial renewal, but over time, repair capacity becomes exhausted. This has two main implications: (i) long-term toxicity should be evaluated using functional measures such as barrier integrity, mitochondrial health, inflammation, and repair ability, and not cell viability alone; (ii) there may be a window during which reducing preservative levels or adding barrier-supporting and mitochondrial-protective agents can minimize cumulative damage. Instead of simply using or avoiding the preservative, this approach encourages formulation and clinical strategies that maintain antimicrobial effects while strengthening tissue resilience.</p>","PeriodicalId":520681,"journal":{"name":"Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics","volume":" ","pages":"615-632"},"PeriodicalIF":2.1,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148451277","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}